Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus.
AuthorDurie, Ian A
Tehrani, Zahra R
Sorvillo, Teresa E
Golden, Joseph W
Welch, Stephen R
Kainulainen, Markus H
Harmon, Jessica R
Mousa, Jarrod J
Karakoc, Hanife Nur
Spengler, Jessica R
Spiropoulou, Christina F
Garrison, Aura R
Sajadi, Mohammad M
Pegan, Scott D
MetadataShow full item record
AbstractCrimean-Congo Hemorrhagic Fever Virus (CCHFV) causes a life-threatening disease with up to a 40% mortality rate. With no approved medical countermeasures, CCHFV is considered a public health priority agent. The non-neutralizing mouse monoclonal antibody (mAb) 13G8 targets CCHFV glycoprotein GP38 and protects mice from lethal CCHFV challenge when administered prophylactically or therapeutically. Here, we reveal the structures of GP38 bound with a human chimeric 13G8 mAb and a newly isolated CC5-17 mAb from a human survivor. These mAbs bind overlapping epitopes with a shifted angle. The broad-spectrum potential of c13G8 and CC5-17 and the practicality of using them against Aigai virus, a closely related nairovirus were examined. Binding studies demonstrate that the presence of non-conserved amino acids in Aigai virus corresponding region prevent CCHFV mAbs from binding Aigai virus GP38. This information, coupled with in vivo efficacy, paves the way for future mAb therapeutics effective against a wide swath of CCHFV strains.
Rights/Terms© 2022. The Author(s).
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/20238
- Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38.
- Authors: Mishra AK, Moyer CL, Abelson DM, Deer DJ, El Omari K, Duman R, Lobel L, Lutwama JJ, Dye JM, Wagner A, Chandran K, Cross RW, Geisbert TW, Zeitlin L, Bornholdt ZA, McLellan JS
- Issue date: 2020 Mar 31
- GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection.
- Authors: Golden JW, Shoemaker CJ, Lindquist ME, Zeng X, Daye SP, Williams JA, Liu J, Coffin KM, Olschner S, Flusin O, Altamura LA, Kuehl KA, Fitzpatrick CJ, Schmaljohn CS, Garrison AR
- Issue date: 2019 Jul
- Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus.
- Authors: Zivcec M, Guerrero LIW, Albariño CG, Bergeron É, Nichol ST, Spiropoulou CF
- Issue date: 2017 Oct
- Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.
- Authors: Hinkula J, Devignot S, Åkerström S, Karlberg H, Wattrang E, Bereczky S, Mousavi-Jazi M, Risinger C, Lindegren G, Vernersson C, Paweska J, van Vuren PJ, Blixt O, Brun A, Weber F, Mirazimi A
- Issue date: 2017 May 15
- Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever.
- Authors: Fels JM, Maurer DP, Herbert AS, Wirchnianski AS, Vergnolle O, Cross RW, Abelson DM, Moyer CL, Mishra AK, Aguilan JT, Kuehne AI, Pauli NT, Bakken RR, Nyakatura EK, Hellert J, Quevedo G, Lobel L, Balinandi S, Lutwama JJ, Zeitlin L, Geisbert TW, Rey FA, Sidoli S, McLellan JS, Lai JR, Bornholdt ZA, Dye JM, Walker LM, Chandran K
- Issue date: 2021 Jun 24